
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a leading life sciences manufacturer that is well positioned to capitalize on the growth trends in cell therapy and diagnostics markets. With a strong global presence and a focus on quality and regulatory compliance, the company is able to provide essential products and services for the pharmaceutical, biotech, academic, and diagnostic markets. Additionally, with a diversified revenue mix and a history of successful M&A, Bio-Techne is well positioned for long-term growth and market consolidation in the industry.
Bears say
Bio-Techne is a life sciences manufacturer that recently divested its loss-making business and reduced its brands from 10 to 3. While the company has a strong exposure to the cell therapy market, it is currently facing challenges in its growth and we expect its margins to be affected by the loss of high margin GMP reagent revenue due to customer timing. The company also has a limited linkage between sustainability metrics and executive compensation. We remain on the sidelines due to the current uncertainty and reduced visibility in the market.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares